A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Exclusion Criteria

• •1. Any major surgery, as determined by the Investigator, within 4 weeks of SBO-154 administration.
• •2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination.
• •3. Known or suspected history of significant drug abuse as judged by the Investigator.
• •4. Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
• •5. Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry.
• •6. Positive exclusion tests: urine pregnancy tests (if applicable), serology tests positive for HIV, HCV, HBsAg (unless they are considered subjects with resolved Hepatitis B and C infection).
• •7. History of any relevant allergy/ hypersensitivity including known immediate or delayed hypersensitivity reaction or idiosyncrasy to biological agents or drug chemically related to SBO-154 or its excipients.
• •8. Received an investigational agent within 30 days or 5 half-lives- whichever is shorter prior to SBO-154 administration.